Current Report Filing (8-k)
August 03 2016 - 4:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
August 3, 2016
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices and
Zip Code)
Registrant’s telephone number, including
area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (
see
General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 Results of Operations and Financial Condition.
On August 3, 2016, Nektar Therapeutics, a Delaware
corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for
the quarter ended June 30, 2016. A copy of the Press Release is furnished herewith as Exhibit 99.1.
On July 27, 2016, Nektar announced that it would
hold a Webcast conference call on August 3, 2016 to review financial results for the quarter ended June 30, 2016. This conference
call is accessible through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com.
The information in this report, including the
exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference
into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit
Number
|
|
Description
|
|
|
|
|
|
|
|
|
|
99.1
|
|
Press Release titled “Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016” issued by Nektar Therapeutics on August 3, 2016.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
NEKTAR THERAPEUTICS
|
|
|
|
August 3, 2016
|
By:
|
/
s/ Gil M. Labrucherie
|
|
|
Gil M. Labrucherie
|
|
|
Senior Vice President and Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
99.1
|
|
Press Release titled “Nektar Therapeutics Reports Financial
Results for the Second Quarter of 2016” issued by Nektar Therapeutics on August 3, 2016.
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Sep 2023 to Sep 2024